- 1. 1,7-Heptanediyl Ester Sulfamic Acid
- [A bisulfamic ester which is similar in structure to busulfan and belongs to the family of drugs known as alkylsulfonate alkylating agents. Hepsulfam forms covalent linkages with nucleophilic centers in DNA, resulting in depurination, base miscoding, strand scission, DNA-DNA and DNA-protein cross-linking, and cytotoxicity. (NCI04) ( NCI )] (UMLS (NCI) C0062540) =Organic Chemical; Pharmacologic Substance ;
| - 51. Hepatic Flexure
- [The bend of the colon at the juncture of its ascending and transverse portions. ( NCI )] (UMLS (NCI) C0227385) =Body Part, Organ, or Organ Component
|
- 2. 3-Heptanol, 6-(dimethylamino)-4,4-diphenyl-, Acetate (Ester), (3S,6S)-(-)-
- [The hydrochloride salt form of levomethadyl acetate, a synthetic mu-receptor agonist with analgesic activity. Levomethadyl acetate hydrochloride mimics the actions of endogenous peptides at CNS opioid receptors, including analgesia, euphoria, sedation, respiratory depression, miosis, bradycardia and physical dependence. Levomethadyl acetate hydrochloride has less severe withdrawal symptoms compared to the morphine-like agents. In addition, with chronic use, levomethadyl acetate hydrochloride produces cross-tolerance to the effects of other mu-receptor agonists, thereby decreasing the physical dependence. ( NCI )] (UMLS (NCI) C0282232) =Organic Chemical; Pharmacologic Substance ;
=LEVOMETHADYL;
=LEVOMETHADYL ACETATE HYDROCHLORIDE 10 MG/ML | - 52. Hepatic Granuloma
- (UMLS (NCI) C0745754) Liver Granuloma;
=Disease or Syndrome ;
|
- 3. 5-Heptenamide, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-,(5Z)-
- [A synthetic prostamide and structural prostaglandin analogue with ocular hypotensive activity. Bimatoprost mimics the effects of the endogenous prostamides and reduces intracocular pressure by increasing outflow of aqueous humor through both the pressure-sensitive outflow pathway (the trabecular meshwork), and the pressure-insensitive outflow pathway (the uveoscleral routes). It is not clear whether bimatoprost lowers intraocular pressure by stimulating F-Prostanoid receptors or by acting on specific prostamide receptors. ( NCI )] (UMLS (NCI) C0937917) Bimatoprost;
BIMATOPROST PREPARATION;
BIMATOPROST UNIDENTIFIED;
=Lipid; Pharmacologic Substance ;
=[OP109] ANTIGLAUCOMA, OTHER;
Unclassified Ingredients =BIMATOPROST 0.03 %;
| - 53. HEPATIC INFARCTION
- (UMLS (ICD9CM) C0151731) =Disease or Syndrome
|
- 4. 5-Heptenoic Acid, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-, 1-methylethyl Ester,(5Z)-
- [A synthetic lipophilic isopropyl ester prodrug of the active compound travoprost free acid, a prostaglandin F2alpha analog with anti-glaucoma property. Upon administration, travoprost is hydrolysed to a free acid by corneal esterases, and then selectively stimulating the prostaglandin F (FP prostanoid) receptor, thereby increasing the uveoscleral outflow which leads to a reduction in intra-ocular pressure. ( NCI )] (UMLS (NCI) C0937916) Travoprost;
TRAVOPROST PREPARATION;
TRAVOPROST UNIDENTIFIED;
=Organic Chemical; Pharmacologic Substance ;
=[OP109] ANTIGLAUCOMA, OTHER;
Unclassified Ingredients =TRAVOPROST 0.004 %;
| - 54. Hepatic Inflammatory Myofibroblastic Tumor
- [A multinodular intermediate fibrocytic neoplasm arising from the liver. It is characterized by the presence of spindle-shaped myofibroblasts, and a chronic inflammatory infiltrate composed of eosinophils, lymphocytes and plasma cells. ( NCI )] (UMLS (NCI) C1333967) Inflammatory Pseudotumor of Liver;
Inflammatory Pseudotumor of the Liver;
Liver Inflammatory Pseudotumor =Neoplastic Process |
- 5. Hep A, adult
- [hepatitis A vaccine, adult dosage ( HL7V3.0 )] (UMLS (HL7) C0694732) =Pharmacologic Substance; Immunologic Factor =Vaccines administered (code = CVX)(parenteral, unless oral is noted);
VaccineType | - 55. HEPATIC INJECTION NEC
- [ ] (UMLS (ICD9CM) C0176890) =Therapeutic or Preventive Procedure
|
- 6. Hep A, NOS
- [An inactivated virus vaccine that provides active immunization against hepatitis A virus (HAV). Immunization with hepatitis A vaccine induces the formation of anti-HAV antibodies which provide protection against hepatitis A infection. (NCI04) ( NCI )] (UMLS (HL7) C0170300) =Organic Chemical; Pharmacologic Substance; Immunologic Factor =Vaccines administered (code = CVX)(parenteral, unless oral is noted);
VaccineType | - 56. Hepatic Leiomyoma
- [A benign smooth muscle neoplasm arising from the liver. It is characterized by the presence of spindle cells with cigar-shaped nuclei, interlacing fascicles, and a whorled pattern. ( NCI )] (UMLS (NCI) C1333968) Leiomyoma of Liver;
Leiomyoma of the Liver;
Liver Leiomyoma =Neoplastic Process |
- 7. Hep A, ped/adol, 2 dose
- [hepatitis A vaccine, pediatric/adolescent dosage, 2 dose schedule ( HL7V3.0 )] (UMLS (HL7) C1548491) =Pharmacologic Substance; Immunologic Factor ;
=Vaccines administered (code = CVX)(parenteral, unless oral is noted);
VaccineType | - 57. Hepatic Leiomyosarcoma
- [An aggressive malignant smooth muscle neoplasm, arising from the liver. It is characterized by a proliferation of neoplastic spindle cells. ( NCI )] (UMLS (NCI) C1333969) Leiomyosarcoma of Liver;
Leiomyosarcoma of the Liver;
Liver Leiomyosarcoma =Neoplastic Process |
- 8. Hep A, ped/adol, 3 dose
- [hepatitis A vaccine, pediatric/adolescent dosage, 3 dose schedule ( HL7V3.0 )] (UMLS (HL7) C1548492) =Pharmacologic Substance; Immunologic Factor ;
=Vaccines administered (code = CVX)(parenteral, unless oral is noted);
VaccineType | - 58. hepatic lipase
- [endothelial bound enzyme produced in the liver which mediates the hydrolysis of triglycerides and phospholipids; plays a central role in normal lipoprotein metabolism. ( CSP )] (UMLS (CSP) C0596690) =Amino Acid, Peptide, or Protein; Enzyme =hydrolase;
|
- 9. Hep A, pediatric, NOS
- [hepatitis A vaccine, pediatric dosage, NOS ( HL7V3.0 )] (UMLS (HL7) C0694731) =Pharmacologic Substance; Immunologic Factor =Vaccines administered (code = CVX)(parenteral, unless oral is noted);
VaccineType | - 59. Hepatic Lipoma
- [A rare benign adipose tissue neoplasm of the liver. ( NCI )] (UMLS (NCI) C1333970) Lipoma of Liver;
Lipoma of the Liver;
Liver Lipoma =Neoplastic Process |
- 10. Hep A-Hep B
- (UMLS (HL7) C1548469) =Pharmacologic Substance; Immunologic Factor ;
=Vaccines administered (code = CVX)(parenteral, unless oral is noted);
| - 60. HEPATIC LOBECTOMY
- [Surgical removal of a lobe of the liver. ( NCI )] (UMLS (ICD9CM) C0193399) =Therapeutic or Preventive Procedure
|
- 11. Hep B, adolescent or pediatric
- [hepatitis B vaccine, pediatric or pediatric/adolescent dosage ( HL7V3.0 )] (UMLS (HL7) C0694733) =Pharmacologic Substance; Immunologic Factor =Vaccines administered (code = CVX)(parenteral, unless oral is noted);
VaccineType | - 61. Hepatic Lobule
- (UMLS (NCI) C0227518) =Body Part, Organ, or Organ Component
|
- 12. Hep B, adolescent/high risk infant
- [hepatitis B vaccine, adolescent/high risk infant dosage ( HL7V3.0 )] (UMLS (HL7) C1552908) =Pharmacologic Substance; Immunologic Factor =VaccineType;
| - 62. Hepatic Lymphoma
- (UMLS (NCI) C1112746) Liver Lymphoma;
Lymphoma of Liver;
Lymphoma of the Liver;
Primary Hepatic Lymphoma =Neoplastic Process ;
|
- 13. Hep B, adolescent/high risk infant2
- (UMLS (HL7) C1548474) =Pharmacologic Substance; Immunologic Factor ;
=Vaccines administered (code = CVX)(parenteral, unless oral is noted);
| - 63. Hepatic MALToma
- (UMLS (NCI) C1333972) Hepatic Mucosa-Associated Lymphoid Tissue Lymphoma;
Liver MALToma;
MALT Hepatic Lymphoma;
MALT Liver Lymphoma;
MALT Lymphoma of Liver;
MALT Lymphoma of the Liver;
MALToma of Liver;
MALToma of the Liver;
Mucosa-Associated Lymphoid Tissue Liver Lymphoma;
Mucosa-Associated Lymphoid Tissue Lymphoma of Liver;
Mucosa-Associated Lymphoid Tissue Lymphoma of the Liver =Neoplastic Process |
- 14. Hep B, adult
- [hepatitis B vaccine, adult dosage ( HL7V3.0 )] (UMLS (HL7) C1552909) =Pharmacologic Substance; Immunologic Factor =VaccineType;
| - 64. Hepatic Mass
- (UMLS (NCI) C0240225) =Disease or Syndrome ;
|
- 15. Hep B, adult4
- (UMLS (HL7) C1548475) =Pharmacologic Substance; Immunologic Factor ;
=Vaccines administered (code = CVX)(parenteral, unless oral is noted);
| - 65. Hepatic Mesenchymal Hamartoma
- (UMLS (NCI) C1333971) Liver Mesenchymal Hamartoma;
Mesenchymal Hamartoma of Liver;
Mesenchymal Hamartoma of the Liver =Neoplastic Process |
- 16. Hep B, dialysis
- [hepatitis B vaccine, dialysis patient dosage ( HL7V3.0 )] (UMLS (HL7) C0694736) =Pharmacologic Substance; Immunologic Factor =Vaccines administered (code = CVX)(parenteral, unless oral is noted);
VaccineType | - 66. hepatic neoplasm
- [new abnormal liver tissue that grows by excessive cellular division and proliferation more rapidly than normal and continues to grow after the stimuli that initiated the new growth cease; do not confuse with intrahepatic neoplasm as that may refer to bile duct neoplasm (BILIARY TRACT NEOPLASM). ( CSP )] (UMLS (CSP) C0023903) =Neoplastic Process ;
=digestive neoplasm;
Hepatic Disorder =Carcinoma of Liver Cells;
HBL;
Carcinoma of Liver Cells;
Liver Neoplasms, Experimental;
Adenoma of Liver Cells |
- 17. Hep B, NOS
- [A non-infectious mixture containing recombinant hepatitis B surface antigen (HBsAg) in a liquid vehicle. Immunization with the hepatitis B vaccine induces the formation of specific anti-hepatitis B antibodies and an active immunity against hepatitis B infection. (NCI04) ( NCI )] (UMLS (HL7) C0062527) =Organic Chemical; Pharmacologic Substance; Immunologic Factor =[IM100] VACCINES;
Unclassified Ingredients;
Vaccines administered (code = CVX)(parenteral, unless oral is noted);
VaccineType | - 67. Hepatic Non-Hodgkin Lymphoma
- (UMLS (NCI) C1333973) Hepatic Non-Hodgkin's Lymphoma;
Non-Hodgkin's Liver Lymphoma;
Non-Hodgkin's Lymphoma of Liver;
Non-Hodgkin's Lymphoma of the Liver;
Primary Hepatic Non-Hodgkin's Lymphoma =Neoplastic Process |
- 18. Hep C
- [hepatitis C vaccine ( HL7V3.0 )] (UMLS (HL7) C1548479) =Pharmacologic Substance; Immunologic Factor ;
=Vaccines administered (code = CVX)(parenteral, unless oral is noted);
VaccineType | - 68. hepatic nuclear factor 1
- [A transcription factor that regulates the expression of a large set of hepatic proteins including SERUM ALBUMIN; beta-fibrinogen; and ALPHA 1-ANTITRYPSIN. It is composed of hetero- or homo-dimers of HEPATOCYTE NUCLEAR FACTOR 1-ALPHA and HEPATOCYTE NUCLEAR FACTOR 1-BETA. ( MSH )] (UMLS (CSP) C0065110) =Amino Acid, Peptide, or Protein; Biologically Active Substance ;
|
- 19. Hep E
- [hepatitis E vaccine ( HL7V3.0 )] (UMLS (HL7) C1548480) =Pharmacologic Substance; Immunologic Factor ;
=Vaccines administered (code = CVX)(parenteral, unless oral is noted);
VaccineType | - 69. Hepatic Parenchyma
- (UMLS (NCI) C0736268) Hepatic Tissue;
=Body Part, Organ, or Organ Component |
- 20. Hepadnaviridae
- [family of hepatotropic DNA viruses which contains double stranded DNA genomes and causes hepatitis in humans and animals, including woodchucks, ground squirrels, and Peking ducks; causes hepatitis, hepatocellular carcinoma, immune complex disease, polyarteritis, and aplastic anemia. ( CSP )] (UMLS (CSP) C0019132) =Virus =DNA virus;
=duck hepatitis B virus;
hepatitis B virus group;
| - 70. hepatic phosphorylase kinase deficiency
- [ ] (UMLS (CSP) C0268147) =Disease or Syndrome ;
|
- 21. heparan sulfate
- [similar to heparin but with some L-iduronic acid residues. ( CSP )] (UMLS (CSP) C0019143) =Carbohydrate; Biologically Active Substance ;
=gag(glycosaminoglycan);
sulfomucopolysaccharide =danaparoid | - 71. Hepatic Portal Vein
- [short thick vein formed by union of the superior mesenteric vein and the splenic vein; enters the liver at the hepatic portal. ( CSP )] (UMLS (NCI) C0032718) =Body Part, Organ, or Organ Component ;
=vein;
|
- 22. Heparan Sulfate Proteoglycan
- [Heparan Sulfate Proteoglycan is an extracellular matrix and vascular basal lamina component. Heparan Sulfate is also an essential co-factor in cell-matrix adhesion processes, in cell-cell recognition systems, and in receptor-growth factor interactions. Degradation by heparanase is a key step in extravasation by tumor cells and migrating leukocytes, as well as in angiogenesis, wound healing, and smooth muscle proliferation. Degradation by heparanase is a key step in extravasation by tumor cells and migrating leukocytes, as well as in angiogenesis, wound healing, and smooth muscle proliferation. In basement membranes, heparan sulfate may stabilize other molecules and influence glomerular permeability and cell adhesion. (From OMIM 142461 and NCI) ( NCI )] (UMLS (NCI) C0062503) =Amino Acid, Peptide, or Protein; Biologically Active Substance ;
| - 72. Hepatic Rhabdomyosarcoma
- [A malignant mesenchymal tumor with skeletal muscle differentiation affecting the liver. ( NCI )] (UMLS (NCI) C1333975) Liver Rhabdomyosarcoma;
Rhabdomyosarcoma of Liver;
Rhabdomyosarcoma of the Liver =Neoplastic Process |
- 23. Heparanase
- [With six potential N-glycosylation sites and hydrophobic stretches suggesting a transmembrane protein, ubiquitous 543-amino acid Heparanase, encoded by human HPSE Gene, is an endoglycosidase (beta-glucuronidase) that degrades heparan sulfate and related proteoglycans in the ECM and vascular basal laminar. Heparan sulfate degradation is key in tumor cell and migrating leukocyte extravasation. Heparanase activity is also important in angiogenesis, wound healing, and smooth muscle proliferation. (from LocusLink, OMIM, and NCI) ( NCI )] (UMLS (NCI) C0062505) =Amino Acid, Peptide, or Protein; Enzyme ;
| - 73. Hepatic Sarcoma
- (UMLS (NCI) C0345906) =Neoplastic Process
|
- 24. Heparanase Gene
- [This gene plays a role in the disassembly of the extracellular matrix by invading cells. ( NCI )] (UMLS (NCI) C1367469) HPSE;
HPSE Gene =Gene or Genome | - 74. Hepatic Schistosomal Granuloma
- (UMLS (NCI) C0343970) =Disease or Syndrome
|
- 25. Heparegen
- (UMLS (NCI) C0162932) =Organic Chemical; Pharmacologic Substance ;
| - 75. Hepatic Sinusoid
- (UMLS (NCI) C0227523) =Body Part, Organ, or Organ Component
|
- 26. heparin
- [poly(glucosamine sulfate-glucuronic acid); endogenous mucopolysaccharide with antithrombin and lipotropic activities; USP injection is used as an anticoagulant. ( CSP )] (UMLS (NCI) C0019134) =Carbohydrate; Pharmacologic Substance; Biologically Active Substance =[BL100] ANTICOAGULANTS;
antithrombin;
gag(glycosaminoglycan);
sulfomucopolysaccharide =Heparin, Low-Molecular-Weight;
HEPARIN SODIUM;
HEPARIN SODIUM (BEEF LUNG);
HEPARIN SODIUM (PORK);
calciparin;
HEPARIN SODIUM;
calcium heparin;
HEPARIN SODIUM (BEEF LUNG);
HEPARIN SODIUM (PORK);
HEPARIN 3 UNT;
| - 76. Hepatic Stellate Cell
- [A star-shaped cell in the liver associated with the development of fibrosis. When stellate cells are activated in response to an injury, they proliferate and synthesize large amounts of extracellular matrix which results in deposition of scar or fibrous tissue. ( NCI )] (UMLS (NCI) C0227531) =Cell
|
- 27. Heparin Binding
- [Heparin Binding involves a biophysical interaction between a biological molecule, such as a protein, and heparin, a sulfated glycosaminoglycan of mixed polysaccharide nature, varying in molecular weight, and released by mast cells and basophils in many tissues. Lipotrophic by activation of lipoprotein lipase, anticoagulant heparin also binds to and enhances antithrombin III activity and inhibits several coagulation factors. ( NCI )] (UMLS (NCI) C1148608) =Molecular Function ;
| - 77. Hepatic Transplantation
- [transference of the liver within an individual, between individuals of the same species, or between individuals of different species. ( CSP )] (UMLS (NCI) C0023911) =Therapeutic or Preventive Procedure ;
=transplantation;
|
- 28. heparin binding growth factor
- [Exhibiting high affinity for heparin, Heparin-Binding Growth Factors (HBGF) control proliferation and differentiation of mesenchymal, epithelial, and neuroectodermal cells. Heparin may store some growth factors in the extracellular matrix, stabilize these proteins, and protect them. For some factors, heparin binding is essential to interact with receptors; it enhances the activity of some HBGF. Class 1 factors comprise acidic proteins, related to (acidic) aFGF. Class 2 factors comprise basic proteins, related to (basic) bFGF. HBGFs appear to be products of different genes; some may not be mitogenic or secreted. Current members include FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, FGF-15, FGF-16, FGF-17, FGF-18, FGF-19, FGF-20, FGF-21, FGF-22, and FGF-23. (NCI) ( NCI )] (UMLS (CSP) C0599765) =Amino Acid, Peptide, or Protein; Biologically Active Substance
| - 78. Hepatic Vascular Disorder
- (UMLS (NCI) C0400923) =Disease or Syndrome ;
|
- 29. heparin cofactor
- [ ] (UMLS (CSP) C0313529) =Amino Acid, Peptide, or Protein; Biologically Active Substance
| - 79. Hepatic Vein
- [Veins which drain the liver. ( MSH )] (UMLS (NCI) C0019155) =Body Part, Organ, or Organ Component ;
|
- 30. heparin eliminase
- [Eliminative cleavage of polysaccharides containing 1,4-linked D-glucuronate or L-iduronate residues and 1,4-a-linked 2-sulfoamino-2-deoxy-6-sulfo-D-glucose residues to give oligosaccharides with terminal 4-deoxy-a-D-gluc-4-enuronosyl groups at their non-reducing ends. (IUBMB Enzyme Nomenclature) ( NCI )] (UMLS (CSP) C0062507) =Amino Acid, Peptide, or Protein; Enzyme ;
=polysaccharide carbon oxygen lyase;
| - 80. hepatic veno-occlusive disease
- [A condition in which some of the veins in the liver are blocked. It is sometimes a complication of high-dose chemotherapy given before a bone marrow transplant and is marked by increases in weight, liver size, and blood levels of bilirubin. ( NCI )] (UMLS (NCI) C0019156) =Disease or Syndrome ;
=Hepatic Disorder;
blood vessel disorder |
- 31. Heparin Lock
- (UMLS (HL7) C0221857) =Medical Device =Administration Device;
| - 81. hepatitis
- [inflammation of the liver and liver disease involving degenerative or necrotic alterations of hepatocytes. ( CSP )] (UMLS (NCI) C0019158) =Disease or Syndrome ;
=Hepatic Disorder;
=Alcoholic Hepatitis;
Hepatitis, Animal;
Chronic hepatitis;
Hepatitis, Toxic;
Hepatitis, Viral, Human |
- 32. heparin sulfate proteoglycan
- [ ] (UMLS (CSP) C0062508) =Organic Chemical; Biologically Active Substance ;
| - 82. hepatitis A
- [hepatitis caused by Hepatovirus (Hepatitis A virus); it can be transmitted through fecal contamination of food or water. ( CSP )] (UMLS (CSP) C0019159) =Disease or Syndrome ;
=Enterovirus Infections;
Hepatitis, Viral, Human;
infectious hepatitis;
|
- 33. hepatectomy
- [excision of all or part of the liver. ( CSP )] (UMLS (NCI) C0019144) =Therapeutic or Preventive Procedure =Operation;
| - 83. hepatitis A virus
- [species in the genus Hepatovirus containing one serotype and two strains: Hepatitis A, human and Simian hepatitis A virus. ( CSP )] (UMLS (CSP) C0376325) =Virus =Hepatovirus;
hepatitis virus |
- 34. hepatic
- [Refers to the liver. ( NCI )] (UMLS (NCI) C0205054) =Body Location or Region ;
| - 84. Hepatitis A Virus Antibody
- [An antibody produced by B lymphocytes in response to hepatitis A enteroviral infection. ( NCI )] (UMLS (NCI) C0062524) =Amino Acid, Peptide, or Protein; Immunologic Factor ;
|
- 35. Hepatic and Biliary Neoplasms
- [A benign or malignant neoplasm involving the liver or the biliary tract. ( NCI )] (UMLS (NCI) C0854196) Hepatic and Biliary Tumors;
Hepatic, Biliary, and Gallbladder Neoplasms;
Hepatobiliary Neoplasm;
Hepato-Biliary Neoplasm;
Hepato-Biliary Tract Neoplasm;
Hepato-Biliary Tract Tumor;
Hepatobiliary Tumor;
Hepato-Biliary Tumor;
Hepatobiliary Tumors;
Neoplasm of Hepato-Biliary Tract;
Neoplasm of the Hepato-Biliary Tract;
Tumor of Hepato-Biliary Tract;
Tumor of the Hepato-Biliary Tract =Neoplastic Process | - 85. HEPATITIS A W/O COMA
- (UMLS (ICD9CM) C0042722) =Disease or Syndrome ;
|
- 36. Hepatic and Intrahepatic Bile Duct Neoplasm
- (UMLS (NCI) C1333976) =Neoplastic Process ;
| - 86. HEPATITIS A WITH COMA
- [ ] (UMLS (ICD9CM) C0153075) =Disease or Syndrome
|
- 37. Hepatic and Intrahepatic Bile Duct Non-Epithelial Neoplasm
- (UMLS (NCI) C1334976) Non-Epithelial Hepatic and Intrahepatic Bile Duct Neoplasm =Neoplastic Process
| - 87. hepatitis B
- [hepatitis caused by hepatitis B virus; one method of transmission is by transfusion of contaminated blood or blood products. ( CSP )] (UMLS (CSP) C0019163) =Disease or Syndrome ;
=Hepatitis, Viral, Human;
Disease (VD), venereal;
Hepadnaviridae Infections;
infectious hepatitis =Hepatitis B, Chronic |
- 38. Hepatic Angiomyolipoma
- [An angiomyolipoma arising from the liver. ( NCI )] (UMLS (NCI) C1333962) =Neoplastic Process
| - 88. Hepatitis B - Consent/Declination
- (UMLS (HL7) C1548856) =Health Care Activity =Consent Type;
|
- 39. Hepatic Arterial Infusion
- [Administration of a fluid form of the drug via a blood vessel into the liver over the sustained period of time. ( NCI )] (UMLS (NCI) C1134564) IHI;
intrahepatic infusion;
Intrahepatic Infusion Procedure =Therapeutic or Preventive Procedure | - 89. hepatitis B antigen
- [antigens of the virion of the Hepatitis B virus or the Dane particle, its surface, core, and other associated antigens, including the hepatitis Be antigens. ( CSP )] (UMLS (CSP) C0019165) =Immunologic Factor ;
=virus antigen;
|
- 40. Hepatic Arteriovenous Malformation
- (UMLS (NCI) C0520557) =Congenital Abnormality ;
| - 90. Hepatitis B Antigen Peptide
- (UMLS (NCI) C0796320) peptide, hepatitis B antigen;
=Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor |
- 41. Hepatic Artery
- [A branch of the celiac artery that distributes to the stomach, pancreas, duodenum, liver, gallbladder, and greater omentum. ( MSH )] (UMLS (NCI) C0019145) =Body Part, Organ, or Organ Component
| - 91. HEPATITIS B CARRIER
- [ ] (UMLS (ICD9CM) C0262505) =Patient or Disabled Group
|
- 42. Hepatic Artery Embolization
- (UMLS (NCI) C0397761) =Therapeutic or Preventive Procedure
| - 92. Hepatitis B Virus Antibody
- [An antibody produced by B lymphocytes in response to hepatitis B hepadnaviral infection. ( NCI )] (UMLS (NCI) C0019164) =Immunologic Factor ;
|
- 43. hepatic cancer
- [ ] (UMLS (CSP) C0345904) =Neoplastic Process
| - 93. hepatitis B virus group
- [DNA virus having complex, double-layered virions 42 nm in diameter; etiologic agent of hepatitis B; associated with the development of hepatocellular carcinomas. ( CSP )] (UMLS (CSP) C0206406) =Virus =Hepadnaviridae;
hepatitis virus |
- 44. hepatic coma
- [ ] (UMLS (CSP) C0019147) =Disease or Syndrome
| - 94. Hepatitis B Virus Related Hepatocellular Carcinoma
- (UMLS (NCI) C1333977) Hepatitis B Virus-Related Hepatocellular Carcinoma =Neoplastic Process ;
|
- 45. hepatic coma/encephalopathy
- [syndrome characterized by central nervous system dysfunction in association with liver failure, including portal-systemic shunts; clinical features include lethargy and confusion, frequently progressing to coma, asterixis, nystagmus, brisk oculovestibular reflexes, decorticate and decerebrate posturing, muscle spasticity, and bilateral extensor plantar reflexes. ( CSP )] (UMLS (CSP) C0019151) =Disease or Syndrome =Hepatic Disorder;
Hepatic Failure;
Brain Diseases, Metabolic, Acquired;
| - 95. Hepatitis B Virus-X
- [Hepatitis B virus X protein; a hepatitis B viral product relevant to hepatocarcinogenesis. ( NCI )] (UMLS (NCI) C0062529) =Amino Acid, Peptide, or Protein; Immunologic Factor ;
|
- 46. Hepatic Disorder
- [impairment of health or a condition of abnormal functioning of the liver. ( CSP )] (UMLS (NCI) C0023895) =Disease or Syndrome ;
=Digestive Diseases;
=fatty liver;
hepatic coma/encephalopathy;
hepatitis;
cerebral pseudosclerosis;
ABSCESS OF LIVER;
cirrhosis;
hepatic neoplasm;
cerebrohepatorenal syndrome;
Hepatic Failure;
liver toxic disorder;
liver circulation disorder;
congenital hepatic porphyria;
liver infection;
Cholestasis, Intrahepatic;
fatty liver;
Hepatic Vein Thrombosis;
hepatic veno-occlusive disease;
hepatitis;
cerebral pseudosclerosis;
Hepatorenal syndrome;
Hypertension, Portal;
ABSCESS OF LIVER;
cirrhosis;
alcohol induced liver disorder;
Liver Diseases, Parasitic;
hepatic neoplasm;
Peliosis Hepatis;
Tuberculosis, Hepatic;
cerebrohepatorenal syndrome;
Hepatic Failure;
Porphyria, Hepatic;
Porphyria, Erythrohepatic;
Focal Nodular Hyperplasia;
Hepatopulmonary Syndrome | - 96. hepatitis C
- [viral disease caused by hepatitis C virus; most common form of post transfusion hepatitis, also is a common acute sporadic hepatitis; may also follow parental drug abuse. ( CSP )] (UMLS (NCI) C0019196) =Disease or Syndrome ;
=Hepatitis, Viral, Human;
Flaviviridae Infections;
infectious hepatitis;
=Hepatitis C, Chronic |
- 47. hepatic duct
- [ ] (UMLS (CSP) C0917710) =Body Part, Organ, or Organ Component
| - 97. HEPATITIS C CARRIER
- (UMLS (ICD9CM) C0400920) =Finding ;
|
- 48. HEPATIC DX PROC NEC
- [ ] (UMLS (ICD9CM) C0176880) =Diagnostic Procedure
| - 98. Hepatitis C Virus Related Hepatocellular Carcinoma
- (UMLS (NCI) C1333978) Hepatitis C Virus-Related Hepatocellular Carcinoma =Neoplastic Process ;
|
- 49. Hepatic Extraskeletal Osteosarcoma
- [An osteosarcoma arising from the liver. ( NCI )] (UMLS (NCI) C1333974) Hepatic Osteogenic Sarcoma;
Hepatic Osteosarcoma;
Liver Osteogenic Sarcoma;
Liver Osteosarcoma;
Osteogenic Sarcoma of Liver;
Osteogenic Sarcoma of the Liver;
Osteosarcoma of Liver;
Osteosarcoma of the Liver;
=Neoplastic Process | - 99. Hepatitis delta without mention of active hepatitis B disease or hepatic coma
- [ ] (UMLS (ICD9CM) C0375011) =Disease or Syndrome
|
- 50. Hepatic Failure
- [severe inability of the liver to function normally, as evidenced by severe jaundice and abnormal levels of ammonia, bilirubin, alkaline phosphatase, glutamic oxaloacetic transaminase, lactic dehydrogenase, and reversal of the albumin/globulin ratio. ( CSP )] (UMLS (NCI) C0085605) =Pathologic Function =Hepatic Disorder;
=MOF syndrome;
hepatic coma/encephalopathy;
Liver Failure, Acute | - 100. Hepatitis delta without mention of active hepatitis B disease with hepatic coma
- [ ] (UMLS (ICD9CM) C0153083) =Disease or Syndrome
|
home
